Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Sangamo Therapeutics (SGMO) over the last 5 years, with Q1 2025 value amounting to $15000.0.

  • Sangamo Therapeutics' Deferred Taxes changed N/A to $15000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $15000.0, marking a year-over-year decrease of 6428.57%. This contributed to the annual value of -$6.3 million for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q1 2025, Sangamo Therapeutics' Deferred Taxes is $15000.0.
  • In the past 5 years, Sangamo Therapeutics' Deferred Taxes registered a high of $182000.0 during Q3 2023, and its lowest value of -$140000.0 during Q4 2023.
  • For the 3-year period, Sangamo Therapeutics' Deferred Taxes averaged around $11400.0, with its median value being $15000.0 (2025).
  • The largest annual percentage gain for Sangamo Therapeutics' Deferred Taxes in the last 5 years was 8714.29% (2024), contrasted with its biggest fall of 9010.99% (2024).
  • Sangamo Therapeutics' Deferred Taxes (Quarter) stood at -$140000.0 in 2023, then skyrocketed by 87.14% to -$18000.0 in 2024, then surged by 183.33% to $15000.0 in 2025.
  • Its Deferred Taxes was $15000.0 in Q1 2025, compared to -$18000.0 in Q4 2024 and $18000.0 in Q3 2024.